This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).
Please refer to www.clinicaltrials.gov identifier NCT01457781 for further information.
Pulmonary Hypertension Program
Page Scovel, RN
A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/ Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease.
Volunteers between the ages of 40 to 80 with COPD (Chronic Obstructive Pulmonary Disease) are invited to participate in a UI study investigating the effects of 2 medications you breath into your lungs daily (Fluticasone Furoate (FF)/Vilanterol (VI) inhalation powder 100/25mcg QD) compared with a placebo. The study will involve multiple visits over the next 4 years. Compensation is available for those individuals who qualify for the study. For more information please call Kim Sprenger at 319-353-8862 or by e-mail at firstname.lastname@example.org.
Kim Sprenger RN
1-800-777-8442 ask for pager 7587
Chest -2 Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Patients who have completed 16 weeks of treatment in the double blind trial CHEST 1
for more information go to www.clinicaltrials.gov Identifier NCT00910429
Cynthia Larew RN 319-356-1028 pager # 2123
AAML08B1 - Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)
This study is organized by Children's Oncology Group (COG). COG is an international research group that conducts clinical trials for children with cancer. Participants in this study are children who have been diagnosed with a condition called Transient Myeloproliferative Disorder (TMD). TMD is found in young babies (less than 3 months old) with Down syndrome and is caused by abnormal blood cells that travel throughout the body. TMD can be life threatening if a subject develops any of the following symptoms: swelling of the organs, enlarged liver, and/or heart and lung problems. The condition of TMD in children with Down syndrome is not well understood. More information about TMD would help doctors to determine the best study treatment for TMD in the future. The purpose of this study is to collect blood samples from TMD subjects for medical research.
Julie de la Garza, 319-356-3749
This program intends to improve the management of pulmonary arterial hypertension (PAH) patients through an evidence-based approach aimed at achieving optimal World Health Organization (WHO) functional class (FC): 1. Improving FC III & IV patients to FC II, 2. Improving FC II patients to FC I, and 3. Maintaining FC II & FC I patients.
Please refer to www.clinicaltrials.gov identifier NCT01389206 for more information.
Cynthia Larew, RN
Copyright © 2013 The University of Iowa. All Rights Reserved.